Oncternal Therapeutics Inc. (ONCT) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Oncternal Therapeutics Inc. (ONCT) Tops Q4 EPS by 1c

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023 4:01 PM EST

Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December 2022Zilovertamab global Phase 3 registrational Study ZILO-301 for the treatment of patients with MCL initiatedPhase 1/2 study for ONCT-808, our autologous CAR-T program targeting ROR1-expressing hematologic malignancies, initiated with initial clinical data expected in late 2023Helpful FDA pre-IND comments received for ONCT-534, our novel dual-action androgen receptor inhibitor (DAARI), supportive of an IND filing by... More